Coverage
-
August 14, 2023
Teva Pharmaceuticals won a major reprieve Monday when a Massachusetts federal judge delayed an impending False Claims Act trial threatening $10 billion in liability and permitted the drugmaker to pursue First Circuit review of a hotly contested FCA issue that has opened a clear circuit split.
11 other articles on this case.
View all »